Stock ONCO ONCOPEPTIDES AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:44 10/05/2024 BST 		5-day change 1st Jan Change
3.34 SEK +14.97% Intraday chart for Oncopeptides AB +12.08% -56.40%
04-15 Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain CI
04-04 Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncopeptides publishes final outcome in the fully guaranteed rights issue
AQ
Annual General Meeting in Oncopeptides AB (publ)
AQ
Oncopeptides publishes the 2023 Annual Report
AQ
Oncopeptides publishes prospectus relating to the rights issue
AQ
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)
AQ
Oncopeptides secures national reimbursement for Pepaxti in Spain
AQ
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain
CI
Oncopeptides announces final terms for the fully guaranteed rights issue
AQ
Oncopeptides releases first quarter 2024 sales
AQ
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024
CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa 
AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
CI
Extraordinary General Meeting in Oncopeptides AB (publ)
AQ
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization
MT
Oncopeptides : Oncopeptalks on the company's rights issue
PU
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026
AQ
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval
AQ
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration
AQ
Oncopeptides : to present at two investor events
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCO Stock
  4. News Oncopeptides AB